Engineered Bacteriophages With Quorum-Sensing Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The rise of antibiotic-resistant pathogenic bacteria, particularly Pseudomonas aeruginosa, poses a significant challenge to phage therapy due to their quorum sensing mechanisms that activate virulence and anti-phage defenses, limiting the effectiveness of phage treatment.
Innovation Solution
Engineering bacteriophages to express inhibitors of quorum-sensing molecules, such as QsdA and AqdC, linked to a promoter regulated by a repressor, ensuring rapid expression during infection without impairing phage replication, thereby disrupting bacterial communication and virulence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bacteriophages are used to kill pathogenic bacteria, then bacterial infection is reduced, but bacteria activate quorum sensing defenses that limit phage therapy effectiveness
Solution Approach 1:
The patent applies preliminary anti-action by engineering phages to express quorum sensing inhibitors (QSI) that preemptively block bacterial quorum sensing signaling pathways before bacteria can activate their anti-phage defense mechanisms. The QSI genes are integrated into the phage genome and expressed during infection, preventing the accumulation of quorum sensing molecules that would otherwise trigger bacterial defense responses, thereby enhancing phage therapy effectiveness.
2Reliability
If phages are engineered to express quorum sensing inhibitors, then bacterial virulence is attenuated, but phage replication may be impaired
Solution Approach 1:
The patent applies dynamics by using inducible or regulated promoter systems to control the expression of quorum sensing inhibitor genes in engineered phages. The expression of QSI genes can be dynamically adjusted based on infection conditions, allowing sufficient inhibition of bacterial virulence while maintaining phage replication capacity. This dynamic regulation ensures that QSI expression does not permanently compromise phage productivity throughout the infectious cycle.
Solution Approach 2:
The patent implements periodic action through temporal control of quorum sensing inhibitor expression during the phage infectious cycle. QSI genes are expressed at specific stages (e.g., during early or mid-infection) when they are most effective at attenuating bacterial virulence, while allowing phage replication to proceed during other phases. This periodic expression pattern balances virulence inhibition with maintenance of phage reproductive success.
3Object-generated harmful factors
If quorum sensing molecules accumulate, then bacterial virulence is activated, but phage therapy efficacy is reduced
Solution Approach 1:
The patent applies the taking out principle by removing or inhibiting quorum sensing signaling molecules from the bacterial system through engineered phage-expressed quorum sensing inhibitors. These QSI proteins bind to and neutralize quorum sensing autoinducers or interfere with their reception, effectively extracting the harmful signaling molecules from the bacterial communication network and preventing them from activating virulence programs that would counteract phage therapy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered anti-QS phages effectively reduce quorum sensing molecule accumulation, attenuate bacterial virulence, and overcome phage resistance, enhancing the efficacy of phage therapy in treating P. aeruginosa infections.
Implementation Method 1
Engineering bacteriophages to express inhibitors of quorum-sensing molecules, such as QsdA and AqdC
Data Source
Figure 1A~1D
Figure 2
Figure 3
AI summary
The present invention relates to engineered bacteriophages encoding and expressing at least one inhibitor of a quorum-sensing molecule. The bacteriophages of the present invention are useful for reducing or eliminating pathogenic bacteria, such as bacterial infections.